Stents

Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable | January 17, 2017 | Dave Fornell

One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable...

Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting | November 02, 2016

November 2, 2016 — Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing...

Medtronic, Drug-Filled Stent, DFS, RevElution trial, first clinical data, TCT 2016, Stephen Worthley
News | Stents Drug Eluting | November 01, 2016

November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel...

News | Stents Drug Eluting | October 31, 2016

October 31, 2016 — Micell Technologies Inc. announced that it presented five-year clinical safety and efficacy...

EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD
Feature | Stents Drug Eluting | October 31, 2016

October 31, 2016 — A major international study has found that...

Svelte Medical Systems, CE Mark, Direct RX, Direct sirolimus-eluting coronary stent rapid exchange system, drug-eluting stent, DES
News | Stents | October 28, 2016

October 28, 2016 — Svelte Medical Systems Inc. announced this week it received CE Mark certification of the Direct...

tryton side branch stent, bifurcation stenting, Cardinal Health
News | Stents Bifurcation | October 28, 2016

October 28, 2016 – Tryton Medical Inc., a primary developer of stents to treat coronary bifurcation lesions, and...

bioresorbable stents, bioabsorbable stents, visualizing the Absorb BVS, dissolving stent, disappearing stent on IVUS and OCT

A comparison of how the Abbott Absorb BVS appears with intravascular ultrasound (IVUS) on the left, and optical coherence tomography (OCT) of the right. The stent is difficult to visualize and sizing is critical, so both modalities can help in bioresorbable stent measurements and to confirm stent apposition. Left image from the Volcano IVUS system and the right image from St. Jude Medical's OCT system

 

Feature | Stents Bioresorbable | October 20, 2016 | Dave Fornell

There has been a lot of interest in the interventional community regarding the Abbott Absorb Bioresorbable Vascular...

transcarotid artery revascularization, TCAR Surveillance Project, Society for Vascular Surgery Patient Safety Organization, SVS PSO,
News | Stents Carotid | October 13, 2016

October 13, 2016 — A surveillance project to evaluate the safety and effectiveness of transcarotid artery...

TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab | September 28, 2016

September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16...

News | Venous Therapies | September 12, 2016

September 12, 2016 — Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp...

Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery
News | Peripheral Arterial Disease (PAD) | August 24, 2016

August 24, 2016 — Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon...

Absorb, bioresorbable stent, BVS, on OCT

An optical coherence tomography (OCT) image of an Absorb bioresorbable stent. The stent struts are clear, allowing light to pass through, and in some cases magnifying the light that passes through under each strut. Image courtesy of St. Jude Medical.

Blog | Stents Bioresorbable | August 16, 2016

There was an explosion of interest in bioresorbable stents immediately following the July 5, 2016 announcement that...

Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell

 

August 5, 2016 — Here are the top 20 most popular current content on the Diagnostic and Interventional...

Gore, Tigris stent, fluoropolymer nitinol stent, peripheral artery disease

The Gore Tigris is a dual-component stent with a unique fluoropolymer / nitinol design.

Technology | Stents Peripheral | August 02, 2016

August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L. Gore & Associates...

Overlay Init